Scientist profiles M-R
Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room E2 40
Administrative Assistant: Peggy Kee
Phone: 416-480-6100, ext. 3505
- M.Sc., 1994, pharmacology, University of Toronto, Canada
- PhD, 1997, pharmacology, U of T, Canada
Appointments and Affiliations:
- Associate scientist, Evaluative Clinical Sciences, Trauma, Emergency & Critical Care Research Program, Sunnybrook Research Institute
- Adjunct faculty, International Centre for Health Innovation, Richard Ivey School of Business, Western University
- Executive director, Health Outcomes and PharmacoEconomic (HOPE) Research Centre, Sunnybrook Research Institute
- Assistant professor, department of pharmacology, U of T
- Co-chair, committee on economic analyses, National Cancer Institute of Canada (NCIC) Clinical Trials Group
- Scientific steering committee member, Ontario HIV Treatment Network
- Member, research ethics board, Sunnybrook Health Sciences Centre
- Faculty, Canadian Foundation for Health Improvement
- Health economic and outcomes research
Dr. Mittmann has conducted and collaborated on research projects in the areas of meta-analysis, economic evaluations, outcomes research and utility assessments. Her research methodologies include the examination of large databases, economic methodologies and decision analysis. Her clinical areas of interest include oncology, cardiology, trauma, infectious disease and health policy.
Dr. Mittmann has received funding as a principal investigator and co-investigator from the Canadian Institutes of Health Research, Canadian Partnership Against Cancer, NCIC, Ontario Institute for Cancer Research, Canadian Breast Cancer Foundation, Ontario Neurotrauma Foundation, Applied Research in Cancer Control, Heart and Stroke Foundation, Canadian Dermatology Foundation, Ontario HIV Treatment Network, Canadian Stroke Network and the Physician Services’ Incorporated Foundation.
Through the clinical trials group of the NCIC and the Canadian Agency for Drugs and Technologies in Health, Dr. Mittmann was the co-principal investigator for the adaptation of economic guidelines for oncology products. This project provides national guidelines for the conduct of economic analysis for oncology products. This work is being used by decision-makers across Canada for the economic evaluation of oncology medications.
- Rocker GM, Verma J, Demmons J, Mittmann N. Number needed to… save? Clinical and Investigative Medicine. 2015:38(1):E11-E14.
- Fowler R, Mittmann N, Geerts W. et al. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): Study protocol for a randomized controlled trial. Trials. 2014;15(1):502 epub ahead of print.
- Mittmann N, Seung SJ, Liu N, Porter J, Leighl N, Trudeau M, Evans W, Earle C. Homecare Utilization and costs in stage IV lung cancer: a Canadian public payer experience. Lung Cancer Management. 2014;3(6): 439–442.
- Mittmann N, Porter NJ, Rangrej J, Seung SJ, Liu N, Saskin R, Cheung MC, Leighl NB, Hoch JS, Trudeau M, Evans WK, Dainty KN, DeAngelis C, Earle CC. Health system costs for stage-specific breast cancer: a population based approach. Current Oncology. 2014;21(6):281–293.
- Mittmann N, Seung SJ, Liu N, Porter J, Saskin R, Hoch JS, Evans WK, Leighl NB, Trudeau M, Earle CC. Population based utilization of radiation therapy by a Canadian breast cancer cohort. Current Oncology. 2014; 21(5): e715–717.
Related News and Stories:
- Spinal cord injury: a manifesto for change. Ontario Neurotrauma Foundation. Expert contributor. Fall 2013 consensus meeting: e-scan moving from blueprint to action
- Counting the cost: Researchers offer guidelines on conducting economic evaluations in patient safety (July 30, 2012)
- Study to examine economics of patient safety: Drs. Etchells and Mittmann lead research on cost of adverse events, supported by Canadian Patient Safety Institute (June 7, 2010)
- Sunnybrook launches ROAM study: Research will open Canada-wide window into management of anticoagulant warfarin (January 15, 2009)